Bio-Techne Corporation
TECH
Rank in Stocks
#1873
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures,... Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Share Price
$72.55
Last synced: 2026-10-16
Market Cap
$11.38B
Change (1 day)
0.03%
Change (1 year)
17.27%
Country
US
Trade Bio-Techne Corporation (TECH)
Category
Healthcare
P/E ratio for Bio-Techne Corporation (TECH)
P/E ratio as of October 2026 TTM: 61.97
According to Bio-Techne Corporation latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 61.97. At the end of 2024 the company had a P/E ratio of 67.18.
P/E ratio history for Bio-Techne Corporation from 2000 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 61.97 | -43.88% |
| 2025 | 110.41 | 64.35% |
| 2024 | 67.18 | 49.36% |
| 2023 | 44.98 | -9.99% |
| 2022 | 49.97 | -59.78% |
| 2021 | 124.26 | 182.43% |
| 2020 | 44.00 | -46.54% |
| 2019 | 82.30 | 86.05% |
| 2018 | 44.24 | -22.03% |
| 2017 | 56.74 | 41.34% |
| 2016 | 40.14 | 18.38% |
| 2015 | 33.91 | 10.18% |
| 2014 | 30.78 | 34.96% |
| 2013 | 22.80 | -6.55% |
| 2012 | 24.40 | -11.39% |
| 2011 | 27.54 | 41.26% |
| 2010 | 19.49 | -14.94% |
| 2009 | 22.92 | -21.66% |
| 2008 | 29.25 | 10.46% |
| 2007 | 26.48 | -2.30% |
| 2006 | 27.11 | -3.27% |
| 2005 | 28.02 | -16.81% |
| 2004 | 33.69 | 21.76% |
| 2003 | 27.67 | -35.05% |
| 2002 | 42.59 | 7.61% |
| 2001 | 39.58 | -60.15% |
| 2000 | 99.34 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -53.55% |
US
|
|
| -28.36 | -145.76% |
US
|
|
| -24.57 | -139.65% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -51.05% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.